Storage-stable lipid vesicles and method of preparation

Claim 2

The process for preparing an aqueous lipid vesicle suspension, wherein a biologically active agent is encapsulated within a unilamellar phopholipid membrane, stable to long term storage at temperatures of -20° C. and below, which comprises rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C., wherein the lipid vesicle suspension is frozen in a liquid propane bath at a temperature of from -190° C. to -141° C.

Claim 3

The process according to claim 1 wherein the encapsulated biologically active agent is inositol hexaphosphate.

Claim 4

The process according to claim 1 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a molar ratio of from 10 to 5:from 4 to 1:from 10 to 3.

Claim 5

The process of claim 3 wherein the membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a ratio of 8:2:7.

Claim 6

A storage stable lipid vesicle suspension prepared according to claim 1 wherein the encapsulated biologically active agent is inositol hexaphosphate in an aqueous, buffered solution.

Claim 7

The storage stable lipid vesicle suspension of claim 5 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a molar ratio of from 10 to 5:from 4 to 1:from 10 to 3.

Claim 8

The storage stable lipid vesicle suspension of claim 6 wherein the phospholipid membrane comprises phosphatidylcholine, phosphatidylserine and cholesterol in a ratio of 8:2:7.

Claim 9

In a process for preparing an aqueous lipid vesicle suspension, a biologically active agent being encapsulated in an aqueous buffered solution within a unilamellar phospholipid membrane in said suspension, and wherein said suspension has a predetermined freezing point, the steps comprising rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C. following preparation of said lipid vesicle suspension, subsequently storing said lipid vesicle suspension at a temperature below said freezing point so as to be stable for long term storage, and thereafter thawing said lipid vesicle suspension to a temperature suitable for said lipid vesicle suspension to be carried into living cells.

Claim 10

In a process for preparing an aqueous lipid vesicle suspension, a biologically active agent being encapsulated in an aqueous buffered solution within a unilamellar phospholipid membrane in said suspension, and wherein said suspension has a predetermined freezing point, the steps comprising rapidly freezing the lipid vesicle suspension at a temperature of from about -196° C. to about -30° C. following preparation of said lipid vesicle suspension, subsequently storing said lipid vesicle suspension at a temperature below said freezing point so as to be stable for long term storage, and thereafter thawing said lipid vesicle suspension to a temperature suitable for said lipid vesicle suspension to be carried into living cells.

Claim 11

The process as claimed in claim 8 further comprising the step of ensonifying said liquid vesicle suspension at an energy of about 100 watts per square centimeter.

Claim 12

The process as claimed in claim 8, wherein said liquid vesicle suspension is stored at a temperature range from about -20° C. to about -30° C.

Claim 13

A storage stable lipid vesicle suspension prepared according to the process of claim 9, and wherein the biologically active agent includes inositol hexaphosphate.

Claim 14

A storage stable lipid vesicle suspension prepared according to the procedure of claim 1 or claim 9.